SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and … – Dove Medical Press

Holly E Gurgle, Karen White, Carrie McAdam-Marx

Department of Pharmacotherapy, University of Utah College of Pharmacy, Sodium Lake City, UT, USA

Abstract: Controversy exists about the selection of second-line procedure when it come to patients along with kind 2 diabetes mellitus (T2DM) that are unable to accomplish glycemic regulate along with metformin procedure alone. Newer pharmacologic therapies when it come to T2DM contain glucagon-enjoy peptide-1 receptor agonists and sodium–sugar cotransporter 2 inhibitors. The two the courses of medication are efficacious, exhibit good effects regard weight, and are associated along with minimal threat of hypoglycemia. The purpose of this review is to compare the health care trial and real-globe efficiency data of glucagon-enjoy peptide-1 receptor agonists versus sodium–sugar cotransporter 2 inhibitors related to A1c reduction, weight loss, cost-effectiveness, cardio outcomes, and security in patients along with T2DM. This review summarizes comparative proof when it come to providers that are recognizing which of the 2 courses might be the a lot of proper when it come to a personal patient.

Keywords: kind 2 diabetes mellitus, GLP-1 receptor agonist, SGLT2 inhibitor, A1c, weight loss, side effect

This job is published and licensed by Dove Health care Press Limited. The complete terms of this license are readily available at http://ift.tt/1X6Iw1k and include the Creative Commons Attribution – Non Industrial (unported, v3.0) License. By accessing the job you hereby accept the Terms. Non-Industrial uses of the job are allowed free of any kind of further permission from Dove Health care Press Limited, given the job is correctly attributed. when it come to permission when it come to Industrial usage of this work, satisfy notice paragraphs 4.2 and 5 of our Terms.

Download Short article [PDF]